← Leaderboards
Ravi Bhasker Patel
University Of Wisconsin-Madison
$2,417,786
Attributed
$2,417,786
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $721.7K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,417,786 · 2
By mechanism
R01$1,788,311 · 1
K08$629,475 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- Zachary Scott Morris$7,480,359
- Jonathan W Engle$3,408,734
- Bryan Patrick Bednarz$4,464,144
- Douglas G McNeel$9,457,366
- Caroline Paula Anne Kerr$144,726
Others in their field
Other Emerging Leaders on “Radiation”
- Leonard Freedman · Leidos Biomedical Research, Inc.$79,138,095
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$31,029,052
- Stephen F Kry · University Of Tx Md Anderson Can Ctr$28,689,457
- Wendy Bergantz · University Of Chicago$13,233,874
Research focus
RadiationTranslationsImproved OutcomePre-ClinicalSiteT-LymphocyteFutureImmunotherapyMelanomaNeuroblastomaRadionuclide TherapyRegimenBiodistributionTissuesDoseDosimetryImageImmuneMalignant NeoplasmsMediatingCellsNeoplastic CellCrispr/Cas TechnologyTumor
Grant awards (8)
VLA-4âtargeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy$611,562
R01 · FY2025 · CA · contact PI
VLA-4âtargeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy$580,985
R01 · FY2024 · CA · contact PI
VLA-4âtargeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy$595,764
R01 · FY2023 · CA · contact PI
Utilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sites$125,895
K08 · FY2023 · CA · contact PI
Utilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sites$125,895
K08 · FY2022 · CA · contact PI
Utilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sites$125,895
K08 · FY2021 · CA · contact PI
Utilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sites$125,895
K08 · FY2020 · CA · contact PI
Utilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sites$125,895
K08 · FY2019 · CA · contact PI